ADMET prediction
Compare absorption, distribution, metabolism, excretion, toxicity, permeability, and physicochemical signals across compound series in one workspace.
Trusted by researchers at leading biotech, pharmaceutical, academic, and materials organizations
Property-aware lead selection
Compare complementary models, keep endpoints and units explicit, and use predictions to decide which measurements and chemical changes are most informative next.
Calculate descriptors, ionization, solubility, and structural alerts that influence exposure and model applicability.
Screen absorption, distribution, metabolism, excretion, and toxicity signals with broad and endpoint-focused models.
Examine membrane transport, efflux, and synthetic practicality, then balance property risks against potency and chemical diversity.
Designed around the research
Available now
Interpret each endpoint in its own units and validation scope, then use predicted risks to prioritize experiments and chemistry—not as definitive safety claims.
Predict a broad panel of ADMET endpoints.
Screen compounds with multitask property models.
Estimate permeability and efflux-related endpoints.
Model passive membrane permeability with molecular simulations.
Assess toxicity and structural risk signals.
Combine ADMET and synthetic-accessibility triage.
From the Neurosnap blog
Property guide
Compare learned and physics-based approaches for membrane transport and oral-bioavailability questions.
Read articleADMET guide
Review compound inputs, endpoint interpretation, and practical use in early lead prioritization.
Read articleSecurity & privacy
Submitted data and generated results remain confidential, with ownership retained by your team.
Only you and authorized colleagues can access submitted data and results.
Your results and intellectual property remain yours. No royalties or equity.
Platform controls help protect sensitive computational research.
Onboarding and integration support help organizations scale confidently.
Prioritize measurable risk
Compare property evidence early, identify decision-critical liabilities, and focus synthesis and assays on the most informative candidates.
